Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 4N222 | IM |
Given intramuscularly; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 66-year-old male patient who received MMR (Priorix) (batch number 4N222, expiry date 30-SEP-2026) for prophylaxis. On 24-MAR-2025, the patient received Priorix (intramuscular). On 24-MAR-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Given intramuscularly). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 25-MAR-2025 The patient was inadvertently given the Priorix intramuscularly instead of subcutaneously, which led subcutaneous injection formulation administered by other route. The reporter consented to follow up.